Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) — Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief Executive Officer in fulfillment of its goal to attract and secure a full-time proven industry leader to move the Company to the next level. Mr. Jackman has over twenty years of multi-industry experience in administration, business and product development, marketing, project and program management, and strategic planning. The Company believes he will provide Alzamend a dynamic blend of bio-pharma experience and corporate leadership to navigate the challenges commonly faced by a developmental biotech company as it pursues the commercialization of its two therapeutic patented solutions for Alzheimer’s disease.
“I am committed to leading this visionary team of scientists and strategic partners to bring novel treatments to the 5.7 million Americans afflicted by this devastating disease,” stated Mr. Jackman. “At Alzamend, we are very familiar with the emotional, physical and economic impact of Alzheimer’s, since a few of our team members are caregivers to loved ones living with the disease.”
Having played an intricate role in the development of therapeutic treatments, products and programs from the research stage to market and commercialization, he has demonstrated a dedicated dual focus of creating value for internal and external stakeholders while developing strategic alliances and cross-function teams to meet and exceed goals. Mr. Jackman has held positions of increasing responsibility at Novartis Pharmaceuticals Corporation, L’Oreal USA, SBM Management Services, and Family Intervention Services. Prior to joining Alzamend Neuro, Mr. Jackman was the Chief Operating Officer of Ennaid Therapeutics, an emerging biopharmaceutical focusing on cures for mosquito borne infectious diseases, such as Zika and Dengue viruses. Additionally, he has been an independent project and management consultant assisting start-ups, Fortune 500 companies and non-profits with major strategic initiatives.
Mr. Milton “Todd” Ault, III, the Founder and Executive Chairman of Alzamend Neuro™ stated, “We are very excited about the appointment of Mr. Jackman as our CEO. Our company is committed to supporting the full product development life cycle of treatment and cures for Alzheimer’s disease and Alzamend is now at the doorstep of the next very important step, FDA registration and application to conduct human clinical trials. It has been our plan since our inception to transition to retain an industry professional to drive our company and our therapeutics to achieve the milestones that are now before us.” Mr. Ault emphasized, “We are grateful to Mr. Mansour who developed our business plan and secured strategic relationships that have well-positioned Alzamend for success. We look forward to his continued role as a Director.”
Mr. Jackman is an advocate for K-12 STEM education having spent over fifteen years mentoring and teaching math to “at-risk” high school students in the Kean University Upward Bound program and Stevens Technical Enrichment Program. Mr. Jackman believes strongly in developing stronger bonds between business and community and eagerly has participated and driven socially responsible initiatives.
Mr. Jackman earned a Master of Science in Management and a Bachelor of Engineering in Mechanical Engineering from Stevens Institute of Technology.
In the U.S., Alzheimer’s disease is the most prevalent form of dementia, estimated to effect over 5.7 million adults today. The company’s goal is to move therapeutic technology out of the research and preclinical testing stages into clinical trials as it works toward commercialization. It is estimated by the Alzheimer’s Association that every 65 seconds, someone in the U.S. develops Alzheimer’s and as many as one in ten adults over 65 have Alzheimer’s. It is also projected that by the year 2050, one in three seniors will have AD or another form of dementia and the disease may affect as many as 88 million adults if a cure is not found. Alzheimer’s disease is one of the costliest chronic diseases to society and estimates are that the total care for Alzheimer’s and other dementias in 2017 cost the nation more than $277 billion.
The Company recommends its shareholders and any interested parties read its public reports and financial statements filed with the Securities and Exchange Commission for further information. All public filings, financial statements, management profiles and other Company information are available on the Company’s web site, www.Alzamend.com™.
About Alzamend Neuro™, Inc.
Alzamend Neuro™, Inc. is a Delaware corporation doing business in the State of Utah. The mission of Alzamend Neuro™ is to support the full product development life cycle of treatment and cures for Alzheimer’s driven by the belief that strong support of research is the foundation for true innovation. The Company is providing current hope through the commercialization of existing patented intellectual property and know-how while simultaneously funding future hope through advanced research and development. Alzamend Neuro’s underlying goal is to get a treatment or cure for Alzheimer’s to market at a reasonable cost as quickly as possible. Far too many suffer daily, patients and caretakers alike, from the burden created by the nation’s 6th leading cause of death and ‘most feared disease’.
The vision of Alzamend Neuro™ has been to license CAO22W®, the patented mutant peptide for use in immunotherapy and LiProSal, a lithium-based ionic cocrystal oral therapy for patients that have long suffered with the effects of AD from the University of South Florida. There are no profound treatments today for Alzheimer’s. With CAO22W® and LiProSal™, the Company is very hopeful that Alzamend can change that.” It is one of the Company’s strategic goals to support the continuing research by the teams at the USF Health Byrd Alzheimer’s Institute and other USF Health Colleges to develop and commercialize their results into meaningful solutions.
From his family’s personal experience with relatives having been afflicted with AD, Mr. Milton “Todd” Ault, III, the Company’s Founder and Executive Chairman, diligently studied the status of treatments and the landscape of medical technology. Mr. Ault selected USF and its formative intellectual property and formed the Company. With over twenty-seven years of experience on Wall Street as an activist driven by his relentless passion for business and technology, Mr. Ault’s efforts have culminated in a commitment to depart from the traditional while forging ahead with an innovative, yet disruptive path to financing the commercialization and the discovery of future solutions.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and those statements are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company cautions that these forward-looking statements are further qualified by other factors. The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.
Investor Inquiries: Email: IR@Alzamend.com™ Company Website: www.Alzamend.com™